David Cella, PhD
Patients with advanced renal cell carcinoma (RCC) treated with cabozantinib (Cabometyx) had similar quality of life (QoL) outcomes as those treated with everolimus (Afinitor).1
- Cella D, Escudier B, Tannir NM, et al. Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase III randomized trial [published online January 29, 2018]. J Clin Oncol. doi: 10.1200/JCO.2017.75.2170.
- Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med.2015;373(19):1814-1823.
... to read the full story